Phio Pharmaceuticals Corp Total Assets
Phio Pharmaceuticals Corp total assets. Based on the latest financial reports, Phio Pharmaceuticals Corp (PHIO) holds total assets worth $17.41 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Phio Pharmaceuticals Corp (PHIO) total market value for the company's overall valuation and market capitalisation.
Total Assets of Phio Pharmaceuticals Corp (2011–2025)
Total assets of Phio Pharmaceuticals Corp from 2011 to 2025. This chart illustrates how Phio Pharmaceuticals Corp's total assets have evolved over time, based on quarterly financial data. See PHIO share price today for real-time trading data and today's change.
Phio Pharmaceuticals Corp - Asset Composition Analysis
Phio Pharmaceuticals Corp Total Assets Breakdown (December 2025)
Phio Pharmaceuticals Corp total assets breakdown as of December 2025. Phio Pharmaceuticals Corp's total assets of $17.41 Million consist of 100.0% current assets and 0.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 97.9% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2011–2025)
This chart illustrates how Phio Pharmaceuticals Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital position of Phio Pharmaceuticals Corp to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Phio Pharmaceuticals Corp's current assets represent 100.0% of total assets in 2025, an increase from 79.0% in 2011.
- Cash Position: Cash and equivalents constituted 97.9% of total assets in 2025, up from 29.7% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2011.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Phio Pharmaceuticals Corp Competitors by Total Assets
Key competitors of Phio Pharmaceuticals Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Phio Pharmaceuticals Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 66.93 | 10.58 | 12.08 |
| Quick Ratio | 66.93 | 10.58 | 12.08 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $17.14 Million | $12.17 Million | $28.58 Million |
Phio Pharmaceuticals Corp - Advanced Valuation Insights
This section examines the relationship between Phio Pharmaceuticals Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.62 |
| Latest Market Cap to Assets Ratio | 0.49 |
| Asset Growth Rate (YoY) | 274.5% |
| Total Assets | $21.49 Million |
| Market Capitalization | $10.49 Million USD |
Valuation Analysis
Below Book Valuation: The market values Phio Pharmaceuticals Corp's assets below their book value (0.49x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Phio Pharmaceuticals Corp's assets grew by 274.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Phio Pharmaceuticals Corp (2011–2025)
The table below shows the annual total assets of Phio Pharmaceuticals Corp from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $21.49 Million | +274.47% |
| 2024-12-31 | $5.74 Million | -38.72% |
| 2023-12-31 | $9.36 Million | -26.92% |
| 2022-12-31 | $12.81 Million | -49.09% |
| 2021-12-31 | $25.17 Million | +59.92% |
| 2020-12-31 | $15.74 Million | +95.78% |
| 2019-12-31 | $8.04 Million | -47.53% |
| 2018-12-31 | $15.32 Million | +273.89% |
| 2017-12-31 | $4.10 Million | -69.41% |
| 2016-12-31 | $13.40 Million | +20.06% |
| 2015-12-31 | $11.16 Million | +21.44% |
| 2014-12-31 | $9.19 Million | -38.49% |
| 2013-12-31 | $14.94 Million | +167.13% |
| 2012-12-31 | $5.59 Million | +230.11% |
| 2011-12-31 | $1.69 Million | -- |
About Phio Pharmaceuticals Corp
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene ex… Read more